These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 22263277)

  • 1. [Overview of locked nucleic acid(LNA)- SPC3649 and its application in HCV treatment].
    Zhang L; Tan WJ
    Bing Du Xue Bao; 2011 Nov; 27(6):614-8. PubMed ID: 22263277
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
    Lanford RE; Hildebrandt-Eriksen ES; Petri A; Persson R; Lindow M; Munk ME; Kauppinen S; Ørum H
    Science; 2010 Jan; 327(5962):198-201. PubMed ID: 19965718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.
    Nunnari G; Schnell MJ
    Front Biosci (Schol Ed); 2011 Jun; 3(3):1032-7. PubMed ID: 21622252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro.
    Alotte C; Martin A; Caldarelli SA; Di Giorgio A; Condom R; Zoulim F; Durantel D; Hantz O
    Antiviral Res; 2008 Dec; 80(3):280-7. PubMed ID: 18625270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-targeting therapeutics for hepatitis C.
    Baek J; Kang S; Min H
    Arch Pharm Res; 2014 Mar; 37(3):299-305. PubMed ID: 24385319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR.
    Morandi L; Ferrari D; Lombardo C; Pession A; Tallini G
    J Virol Methods; 2007 Mar; 140(1-2):148-54. PubMed ID: 17175034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioinformatics analysis of the structure and function correlated to interferon sensitivity of HCV core protein].
    Cheng L; Guo Y; Hong GH; Mao Q
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):96-8. PubMed ID: 21863627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense gets a grip on miR-122 in chimpanzees.
    Branch AD; Rice CM
    Sci Transl Med; 2010 Jan; 2(13):13ps1. PubMed ID: 20371461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response.
    Donadel E; Pontisso P; Ruvoletto MG; Gerotto M; De Salvo G; Chemello L; Casarin C; Alberti A
    J Med Virol; 1998 Jan; 54(1):7-11. PubMed ID: 9443103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miravirsen works against hepatitis C virus.
    BMJ; 2013 Apr; 346():f2069. PubMed ID: 23553883
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology of hepatitis C infection.
    Drazan KE
    Liver Transpl; 2000 Jul; 6(4):396-406. PubMed ID: 10915159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis C IRES: translating translation into a therapeutic target.
    Jubin R
    Curr Opin Mol Ther; 2001 Jun; 3(3):278-87. PubMed ID: 11497352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and analysis of hepatitis C virus by a combined RT-PCR method: variation in the 5' non-coding region of the viral genome.
    Karachristos A; Linardopoulos S; Ergazaki M; Spandidos DA
    J Med Microbiol; 1995 May; 42(5):367-71. PubMed ID: 7752217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.